RestaX Effluvium: NO RISK TO THOSE WHO TAKE IT!

news

RESTAX EFFLUVIUM: NO RISK FOR THOSE WHO TAKE IT!

Following numerous appearances of defamatory and outright false and misleading articles on the web, the company Wikenfarma would like to clarify what is really happening with the product RESTAX EFFLUVIUM. Some people are talking about seizures, recalls, recalls, but the truth is that the product with the old non-compliant formulation has not been on the market for more than a year. A great many newspapers and online journals are riding the wave of sensationalism without, in fact, knowing what the real situation is.

There are even those who speak of a chemical risk, but the company is keen to assure how these claims are totally false and unsubstantiated. In fact, RestaX Effluvium continues to be the most prescribed product by dermatologists in Italy. We will immediately explain why.

First a premise: contrary to all the sensationalist headlines on the web, we would like to reassure all readers that taking RestaX Effluvium causes NO COLLATERAL EFFECTS for two main reasons:

The formulation CURRENTLY on the market is compliant with current regulations, as it was CHANGED in September 2022, and the lots defined as “noncompliant” have not been on the market for a full 15 months.
The old formulation itself did NOT present ANY health risks, and now we explain why.

RestaX Effluvium: let's have clarity!

What triggered all this confusion? The answer is much simpler than it sounds: the old formulation of RestaX Effluvium contained an active ingredient called Griffonia simplicifolia (at 60 percent concentration and enriched with 5-hydroxytryptophan). European legislation has tightened regulations regarding this active ingredient by listing it as a novel food and declaring it as not usable in dietary supplements. But, in fact, the product is not found to be risky in any way.

But what does this mean?

It does not mean that there are risks for those who took it; on the contrary, a doctor’s prescription was simply required for taking such an active ingredient with such a high concentration. And contrary to all the reports circulating among various blogs and self-styled newspapers, the “risks” ended there.

There was no recall and no maxi-sequestration: the product with the old formulation has not been on the market for at least 15 months, as Wikenfarma, just by virtue of being No. 1 in Trichology, changed the formulation of RestaX Effluvium in September 2022 and all the packages currently on the market are found to be IN COMPLIANCE WITH CURRENT REGULATIONS, as the formulation of the product has been changed while maintaining the benefits.

So can RestaX Effluvium be taken?

The answer is: absolutely yes!

The important thing is to look for information on reliable and serious websites. All batches of the product declared to be non-compliant with the regulations have already been reported well in advance and NONE of them are currently on the market, in fact there has been no seizure or recall of the indicated batches.

The new formulation was launched last year and modified in decidedly unsuspected times, precisely because Wikenfarma is a company that cares about following European procedures and protocols, even when regulations are not yet effective at the national level (as in this case).

Maxi-seizure or maxi-media hoax?

Unfortunately, unclear information is likely to bounce confusingly between social channels and websites, but it hardly turns out to be true and to the point. All the media fuss raised by this mendacious information has contributed to the creation of a MAXI-BUFALA regarding the product RestaX Effluvium and its alleged dangerousness: precisely because of this, Wikenfarma would like to emphasize what has been said before.

RestaX Effluvium does NOT present any side effects to the health of those taking it, just as it did not with the old formulation. The product currently on the market is IN COMPLIANCE to current national and European regulations: those who take RestaX Effluvium can sleep soundly!